Long read sequencing of the 16S-23S rRNA operon to characterize gut microbial changes associated with multiple sclerosis

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

The microbiome has emerged as a major contributor to human health and disease. Numerous sources implicate shifts in the gut microbiome as potentially pathologic for a variety of autoimmune diseases. For many of these diseases, changes in the microbiome are subtle and descriptive in nature. Further, limitations in 16S rRNA sequencing make inter-study comparisons and identification of causative microbes difficult. This heterogeneity can be traced to the evolution of sequencing technology and variability in sampling methodology. For example, in multiple sclerosis, numerous research groups have described shifts in gut microbes among patients, but identified taxa have been inconsistent across studies. To address these challenges, we have implemented long-amplicon sequencing of the 16S-ITS-23S rRNA operon, which, when combined with machine learning-based denoising, allows reliable taxonomic resolution down to the species and strain levels, facilitating more definitive comparison between clinical cohorts and possible identification of causative microbes. Using these technologies, we set out to study the microbiomes of new-onset treatment-naïve relapsing-remitting multiple sclerosis at baseline and post B cell depletion therapy, with healthy donors as a control group. We identify Bacteroides emerge as being enriched in the gut microbiota of MS patients. This trend reverses upon initiation of effective immunomodulatory therapy for MS. Manipulation of the gut microbiome is a putative mechanism of action by which immunomodulatory therapies may impact MS and other immune-medicated diseases. Further exploration of these phenomena may open new avenues for understanding and treating MS.

Learning Objectives:

1. Understand the pros/cons of generating and processing long-read microbiome data

2. Identify differences between the microbiome of healthy subjects and MS patients at baseline

3. Understand how immunotherapy may influence the microbiome of MS patients


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
APR 19, 2021 8:00 AM PDT
C.E. CREDITS
APR 19, 2021 8:00 AM PDT
Date: Apri 19, 2021 Time: 8:00am PDT, 5:00pm CEST Since the inception of modern biological research, BioSafety has evolved into a critical consideration in Good Laboratory Practices (GLP). Wi...
JUN 22, 2021 10:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUN 22, 2021 10:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: June 22, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Antimicrobial resistance (AMR) has emerged as one of the principal public health problems of the 21st century. It threatens the effectiv...
Loading Comments...
Show Resources